| Tyzeka (telbivudine) / Novartis |
ChiCTR-TRC-09000341: A 24-week, parallel-group, open-label, randomized trial comparing Telbivudine with Entecavir treatment in HBeAg-positive chronic hepatitis B patients |
|
|
| Completed | 4 | 124 | | received Telbivudine alone ;received Entecavir alone | The First Affiliated Hospital of Wenzhou Medical College; Level of the institution：, Self-finance | Chronic hepatitis B | | | | |
ChiCTR-TCC-09000420: A study on efficiacy and safety of telbivudine in interruption of intrauterine infection of hepatitis B virus |
|
|
| Completed | 4 | 200 | | no ;telbivudine 600mg/day, oral | The Nangjing Second Hospital Affiliated Southeast Medical University; Level of the institution：, Self-finance | Intrauterine infection 0f hepatitis B virus | | | | |
ChiCTR-OCC-11001776: The efficacy of entecavir and telbivudine in HBeAg positive chronic hepatitis B patients with high viral load |
|
|
| Completed | 4 | 100 | | Telbivudine ;Entecavir | Center of infectious Diseases, West China Hospital of Sichuan University; Center of infectious Diseases, West China Hospital of Sichuan University, No | Chronic Hepatitis B | | | | |
ChiCTR-ONRC-11001495: Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir: a prospective controlled study |
|
|
| Completed | 4 | 80 | | Telbivudine 600 mg/day , Adefovir 10 mg/day ;Lamivudine 100 mg/day , Adefovir 10 mg/day | Center of Infctious Diseases, West China Hospital of Sichuan University; Center of Infctious Diseases, West China Hospital of Sichuan University, self-funding | Chronic hepatitis B | | | | |
ACTRN12614001224617: A randomized controlled trial to study whether telbivudine can prevent virus reactivation and improve the prognosis after liver resection in patients with hepatitis B virus-related hepatocellular carcinoma |
|
|
| Active, not recruiting | 4 | 200 | | | ZHOU Wei-ping, The State Key Project on Infectious Diseases of China: 2012ZX10002010, 2012ZX10002016, Science Fund for Creative Research Groups, NSFC, China: 81201940, National Science Foundation of China: 81201555 | hepatitis B virus-related hepatocellulcar carcinoma | | | | |
ChiCTR-OPC-16008318: Clinical study on the efficacy and safety of telbivudine for interrupting mother-to-child transmission of hepatitis B virus (HBV) in pregnant women |
|
|
| Completed | 4 | 77 | | LdT treatment (600 mg/day) from 28th. week of pregnancy until the delivery day, in case of confirmed CHB during pregnancy, they continued to use LdT after delivery according to the guideline of CHB treatment in China [22], and no breast-feeding during the LdT treatment. ;HBIG (200 IU dose once) was administered by intramuscular injection three times at the 28th., 32th., and 36th. gestational weeks. | the first Affiliated Hospital of Jinan University; the first Affiliated Hospital of Jinan University, Science and Technology Planning Project of Guangdong Province, China | chronic hepatitis B | | | | |
ChiCTR-IPR-15006587: A randomized controlled trial:Evaluating the impact of telbivudine treatment on the prognosis of HBV-related liver cancer and posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma. |
|
|
| Completed | 4 | 200 | | telbivudine ;No intervention | Eastern Hepatobiliary Surgical hospital; Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Eastern Hepatobiliary Surgery Hospital and the Shanghai Science and Technology Commission Research Fund | hepatitis B-related hepatocellular carcinoma | | | | |
ChiCTR-OPC-16007899: Telbivudine to prevent mother-to-infant transmission of HBV in early and mid pregnancy |
|
|
| Completed | 4 | 188 | | treated with telbivudine from12 weeks of gestation，Telbivudine was discontinued at postpartum 12 weeks.; treated with telbivudine from20 to 28 weeks of gestation，Telbivudine was discontinued at postpartum 12 weeks. ;wasn’t given telbivudine treatment | Qingdao Chengyang People's Hospital; Qingdao Chengyang People’s Hospital, the Research Foundation of the Chengyang District | Chronic hepatitis B | | | | |
| Completed | 4 | 200 | | None ;None ;None | Key Laboratory of Reproductive Genetics, Ministry of Education; Women's Hospital, School of Medicine, Zhejiang University, Foundation of Education Department, Zhejiang (Y201225448) | HBV | | | | |
ChiCTR-TRC-13004454: Optimal options of antiviral programs in CKD combined with chronic hepatitis B immunosuppressive treatment patients. |
|
|
| Recruiting | 4 | 114 | | Telbivudine treatment ;entecavir | Nephrology Department, the First Affiliated Hospital, Third Military Medical University; the First Affiliated Hospital, Third Military Medical University, Clinical and scientific research special fund of Third Military Medical University | Chronic kidney disease combined with Chronic Hepatitis B infection | | | | |
ChiCTR-OPC-16008331: Cohort study on Tenofovir and Telbivudine in preventing mother-to-infant transmission of hepatitis B virus in pregnant women with high viremia |
|
|
| Recruiting | 4 | 150 | | Tenofovir (300mg) was taken every day from 28th-32nd weeks of pregnancy to the delivery day ;Telbivudine (600mg) was taken every day from 28th-32nd weeks of pregnancy to the delivery day | the first Affiliated Hospital of Jinan University; the first Affiliated Hospital of Jinan University, Science and Technology Planning Project of Guangdong Province, China | chronic hepatitis B | | | | |
ChiCTR-OPN-17012206: Study on Tenofovir combination with Telbivudine in HBeAg positive Chronic Hepatitis B patients |
|
|
| Not yet recruiting | 4 | 100 | | Tenofovir 300mg 1 / day, combined with telbivudine 600mg 1 / day ;Tenofovir 300mg 1 / day | PLA 81th Hospital; PLA 81th Hospital, Foundation of Beijing Medical Health and Public Welfare | chronic hepatitis B | | | | |
ChiCTR-OPC-16010157: Study on efficacy and safety of telbivudine combined with adefovir dipivoxil treatment of chronic hepatitis B patients |
|
|
| Recruiting | 4 | 200 | | DV 10mg +LdT 600mg QD ;DT 600mg +ADV 10mg QD ;ETV 0.5 mg QD | Tianjin 2nd People's Hospital; Tianjin 2nd People's Hospital, NA | Chronic hepatitis B | | | | |
ChiCTR2100048992: A prospective cohort study of potent and rapid inhibition of viral replication in the treatment of chronic hepatitis B |
|
|
| Not yet recruiting | 4 | 400 | | Tenofovir disoproxil fumarate ;Tenofovir alafenamide fumarate ;Tenofovir disoproxil fumarate combined Telbivudine ;Tenofovir fumarate combined with Telbivudine | The Third Affiliated Hospital of Sun Yat-sen University; The Third Affiliated Hospital of Sun Yat-sen University, Zhongguancun Precision Medicine Foundation | hepatitis B | | | | |
2016-004825-17: A Proof of concept study to investigate the effect of the antiviral medication "Telbivudine" in patients with inflammatory heart muscle disease caused by the Parvovirus Eine Machbarkeitsstudie über die Wirksamkeit des antiviralen Medikaments "Telbivudine" bei Patienten mit entzündlicher Herzmuskelerkrankung, die durch das Parvovirus verursacht ist |
|
|
| Ongoing | 2 | 25 | Europe | Sebivo, Tablet, Sebivo | Charité Universitätsmedizin Berlin, BMBF | Parvovirus B19-induced inflammatory cardiomyopathy Parvovirus B19-induzierte inflammatorische Kardiomyopathie, Parvovirus B19-induced inflammation of the heart muscle Parvovirus B19-ausgelöste Entzündung des Herzmuskels, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR-TRC-10001100: The protective effect of Telbivudine combined Radiotherapy for patients with primary liver cancer with hepatitis B virus infection |
|
|
| Completed | 1/2 | 100 | | Radiotherapy only ;Radiotherapy combined Telbivudine | Zhongshan Hospital of Fudan University; Beijing Novartis Pharma Ltd., Beijing Novartis Pharma Ltd. | primary liver cancer with hepatitis B virus infection | | | | |
ChiCTR-PRC-11001541: A prospective study for the efficacy and safety of Telbivudine in hepatitis B virus infected pregnant woman to prevent mother-child transmission. |
|
|
| Recruiting | 1 | 200 | | All infants were vaccinated with HBV vaccine 20mg(within 12 hours of birth, at week 4, and at week 24) and 200 IU of HBIg within 2h of birth and in 15 days or 1 month. ;Cases received telbivudine 600mg per day from week 24-32 of gestation. All infants were vaccinated with HBV vaccine 20mg(within 12 hours of birth, at week 4, and at week 24) and 200 IU of HBIg within 2h of birth and in 15 days or 1 month. | Institute for Infectious Diseases, Southwest Hospital, Third Military Medical University; The State Nuture Science Foundation, China, From the national key scientific research project . | Hepatitis B virus (HBV) infection is a serious clinical problem.In the Asia-Pacific region, the mother-to-child transmission of HBV from hepatitis B surface antigen (HBsAg)-positive mothers to their i | | | | |
ChiCTR-OCC-12001987: The effects of telbivudine treatment on circulating Tregs and its significance in CHB patients |
|
|
| Completed | N/A | 41 | | none ;telbivudine | Institute for Infectious Diseases, Southwest Hospital, Third Military Medical University; The State Nuture Science Foundation, China, From the national scientific research project | Hepatitis B | | | | |
ChiCTR-TRC-09000615: Pre-operative application of Teltivudine to improve hepatic function in patients with Primary hepatic cancer and positive HBV-DNA of low-concentration |
|
|
| Completed | N/A | 60 | | Telbivudine was given before operation ;no antivirus drug before operation | East hepatobiliary hospital; Level of the institution：, Self funding | Primary liver cancer (hepatic cell carcinoma, HCC) | | | | |
